PCSK9 Inhibition and Risk of Diabetes: Should We Worry?

Creative Commons License

Carugo S., Sirtori C. R., Corsini A., Tokgozoglu L., Ruscica M.

CURRENT ATHEROSCLEROSIS REPORTS, vol.24, no.12, pp.995-1004, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 24 Issue: 12
  • Publication Date: 2022
  • Doi Number: 10.1007/s11883-022-01074-y
  • Journal Name: CURRENT ATHEROSCLEROSIS REPORTS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE
  • Page Numbers: pp.995-1004
  • Keywords: PCSK9, New-onset diabetes, beta-cells, Evolocumab, Alirocumab, DENSITY-LIPOPROTEIN CHOLESTEROL, LOWERING GENETIC-VARIANTS, LDL-CHOLESTEROL, STATIN THERAPY, GLUCOSE-HOMEOSTASIS, INSULIN-SECRETION, SAFETY, EVOLOCUMAB, EFFICACY, ASSOCIATION
  • Hacettepe University Affiliated: Yes

Abstract

Purpose of Review Since the clinical benefit of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors occurs in a setting of reducing low-density lipoprotein-cholesterol (LDL-C) to unprecedentedly low levels, it becomes of interest to investigate possible adverse effects pertaining to the risk of new-onset diabetes (NOD).